MULTIPLE MYELOMA

Cilta-cel shows promising long-term survival rates in relapsed/refractory multiple myeloma, suggesting potential for a cure in standard-risk patients.

Outpatient CAR T-cell therapy shows promising efficacy and manageable safety in treating relapsed multiple myeloma, with high response rates and minimal long-term toxicity.

Bispecific antibodies talquetamab and teclistamab show promising results in treating relapsed/refractory multiple myeloma with extramedullary disease, achieving high response rates.

AZD0120 demonstrates impressive early efficacy and safety in treating relapsed/refractory multiple myeloma, with a 96% response rate and rapid manufacturing.

Linvoseltamab shows promising efficacy and safety as a monotherapy for newly diagnosed multiple myeloma, offering a simpler treatment alternative.

Cevostamab shows promising efficacy and manageable safety in treating relapsed/refractory multiple myeloma, offering a convenient subcutaneous administration option.

Gintemetostat shows promising efficacy and safety in heavily pretreated multiple myeloma patients, paving the way for future combination therapies.

New research reveals KRd therapy significantly enhances progression-free survival in newly diagnosed multiple myeloma compared to traditional VRd treatment.

Cilta-cel therapy shows improved outcomes in earlier treatment lines for relapsed/refractory multiple myeloma, enhancing immune fitness and survival rates.

Peter Voorhees, MD, discusses the evolving treatment landscape for smoldering multiple myeloma, highlighting new therapies and clinical trial opportunities.

During a live event, Thomas G. Martin, MD, discussed the importance of controlling disease and avoiding barriers to access so patients with multiple myeloma can receive CAR T-cell therapy.

FDA approves daratumumab for high-risk smoldering multiple myeloma, transforming treatment strategies and enhancing patient outcomes in early intervention.

Selinexor-based therapies enhance T-cell activation in multiple myeloma patients, revealing potential strategies for improving treatment efficacy and overcoming resistance.

A study reveals a U-shaped relationship between BMI and CAR T-cell therapy outcomes in multiple myeloma, highlighting the need for further research.

Isatuximab shows promising efficacy and safety for relapsed AL amyloidosis, achieving high response rates and favorable survival outcomes in a phase 2 trial.

The FDA approves new denosumab biosimilars, expanding treatment options for osteoporosis and cancer-related bone issues, enhancing patient access to care.

Bispecific and trispecific antibodies show efficacy in multiple myeloma, moving into earlier lines of therapy.

The FDA clears the EXENT System, enhancing multiple myeloma diagnosis with automated workflows and improved sensitivity for clinical laboratories.

During a live event, Thomas G. Martin, MD, discussed updated findings from the CARTITUDE-1 trial of cilta-cel and what they signify for patients with no disease progression at 5 years.

The FDA has approved daratumumab and hyaluronidase for the treatment of patients with high-risk smoldering multiple myeloma.

Talquetamab and daratumumab show high efficacy in treating relapsed/refractory multiple myeloma, with promising response rates and manageable safety profiles.

FDA approves new combinations for multiple myeloma treatment, enhancing survival rates and addressing unmet needs in patient care.

The FDA fast-tracks pamlectabart tismanitin, a promising treatment for relapsed multiple myeloma, enhancing its development and review process.

Belantamab mafodotin (Blenrep), pomalidomide (Pomalyst), and dexamethasone (BPd) was well tolerated and led to deep responses in patients with high-risk multiple myeloma.

Cevostamab delivered feasible and well-tolerated antitumor activities post CAR T-cell therapy in patients with heavily pretreated multiple myeloma.